FDA Fast-Track Approval

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer

Phase III data validate December’s accelerated FDA decision by confirming the encorafenib, cetuximab and mFOLFOX6 combination as a new standard of care for this aggressive molecularly defined disease.